News Story: Full Text
Sponsored By
Tocagen Clinical Trial
Please Click On The Above Banner For More Details
Braintumor Website

 

The Musella Foundation announced that it has awarded Tocagen Inc. a grant to support preclinical testing the compatibility of Tocagen’s therapy with 5-ALA or tumor treating fields.

Al's Comment:

 This is one of the grants that I am most proud of. It is usually very hard to get different companies to work together on a project like this, but these 3 companies were eager and willing to work together to speed up the search for the cure!


Posted on: 06/05/2015

 The Musella Foundation announced that it has awarded Tocagen Inc. a grant to support preclinical testing  of Tocagen’s therapy with 5-ALA or tumor treating fields. 
 
 
Hewlet, NY, June 5, 2015 – The Musella Foundation For Brain Tumor Research & Information, Inc. (Musella Foundation), a non-profit organization dedicated to improving the lives of families dealing with brain cancer, announced that it has awarded Tocagen Inc. (Tocagen) a grant to support preclinical testing of Tocagen’s therapy with 5-ALA or tumor treating fields. Tocagen is a private biopharmaceutical company developing novel immuno-oncology treatments for cancer.
 
“We are pleased to see the continued progress Tocagen has made with Toca 511 & Toca FC towards offering a potential new treatment option for patients with primary brain cancer.” said Al Musella, DPM, President of the Musella Foundation. “This grant will help support important research to identify potential future combinations of Toca 511 & Toca FC with other treatment modalities.”
 
 “We are thankful to the Musella Foundation for their continued support for our program as we advance towards a registrational Phase 2/3 trial (Toca 5) in subjects with recurrent high grade glioma” said Harry Gruber, MD, the CEO of Tocagen. “This grant award will enable important research that we hope will ultimately make a difference in the lives of patients suffering from this disease.”
Tocagen is currently enrolling patients across the US in its investigational clinical trials of Toca 511 (vocimagene amiretrorepvec), for injection in combination with Toca FC (flucytosine), extended-release tablets. These multicenter studies are evaluating patients with recurrent high-grade glioma, who have had prior surgery and chemoradiation.
 
 
For more information about Tocagen or Toca 511 please visit www.tocagen.com or www.clinicaltrials.gov using the identifier NCT01470794, NCT01156584, NCT01985256, or NCT02414165.
 
 
About the Musella Foundation
The Musella Foundation For Brain Tumor Research & Information, Inc is a 501(c)3 non- profit organization dedicated to speeding up the search for the cure of brain tumors, as well as helping families deal with the diagnosis of brain cancer, by funding innovative brain tumor research, education, advocacy, emotional and financial support for families that are dealing with brain tumors and organizing the brain tumor community to work together as an army to fight the disease. The “Clinical Trials and Noteworthy Treatments For Brain Tumors” website at http://virtualtrials.com, the “Brain Tumor Copayment Assistance Program”  website at http:// braintumorcopays.org, “The National Walk To End Brain Tumors” website at http://walktoendbraintumors.org and the “Grey Ribbon Crusade”  website at http://greyribboncrusade.org/ are all maintained by the Musella Foundation For Brain Tumor Research & Information.
 

 


Click HERE to return to brain tumor news headlines


Home | Brain Tumor Guide | FAQs | Find A Treatment
Noteworthy Treatments | News | Virtual Trial | Videos | Novocure Optune® | Newsletter
Donations | Brain Tumor Centers | Survivor Stories | Temodar®
Fundraising For Research | Unsubscribe | Contact Us

Copyright (c) 1993 - 2018 by:
The Musella Foundation For Brain Tumor Research & Information, Inc
1100 Peninsula Blvd
Hewlett, NY 11557
888-295-4740